Selenium Deficiency and Thyroid Health: What the Evidence Shows

Why the Thyroid Depends on Selenium More Than Any Other Organ

The thyroid accumulates selenium at concentrations no other tissue matches, and there is a straightforward biochemical reason for that. Selenium is the structural component of at least 11 selenoproteins that are directly expressed in thyroid cells. Three enzyme families are especially relevant to clinicians: the iodothyronine deiodinases (DIO1, DIO2, DIO3), the glutathione peroxidases (particularly GPx1 and GPx4), and thioredoxin reductases (TrxR1, TrxR2).

Deiodinases convert the relatively inactive prohormone thyroxine (T4) into triiodothyronine (T3), the metabolically active form. DIO1 and DIO2 catalyze the outer-ring deiodination that produces T3, while DIO3 inactivates excess T3 and T4. Without sufficient selenium incorporated into the active site of these enzymes, peripheral T4-to-T3 conversion falls, and a patient can present with symptoms consistent with hypothyroidism even when their total T4 appears normal on a standard panel. [1]

Thyroid hormone synthesis itself generates significant amounts of hydrogen peroxide as a byproduct. The selenium-dependent glutathione peroxidases neutralize that oxidative load. When selenium is deficient, hydrogen peroxide accumulates inside follicular cells, damages thyroid tissue, and amplifies the autoimmune response already present in conditions like Hashimoto's thyroiditis. One meta-analysis of 16 randomized controlled trials (N=1,382) published in Thyroid confirmed that selenium supplementation significantly reduced both TPO-Ab and thyroglobulin antibody (Tg-Ab) concentrations compared with placebo. [2]

Serum selenium below 70 mcg/L is associated with measurable reductions in GPx activity and reduced selenoprotein P, the main transport protein for selenium in circulation. [3] Populations in central Europe, sub-Saharan Africa, and parts of China are particularly at risk given the low selenium content in local soils.

Selenium Deficiency and Hypothyroidism

Low selenium status does not directly cause overt hypothyroidism on its own, but it compounds the risk substantially. In a cross-sectional analysis of 6,152 adults from the U.S. National Health and Nutrition Examination Survey (NHANES 2007 to 2012), lower urinary selenium was independently associated with higher TSH concentrations after adjustment for iodine status, BMI, and smoking. [4] A TSH trend toward the upper end of the reference range, even when still technically "normal," can translate into real symptoms: fatigue, cold intolerance, slow cognition, and dry skin.

The T4-to-T3 conversion deficit is the main mechanism. DIO2 is the enzyme responsible for most intracellular T3 production in target tissues including the brain and skeletal muscle. Selenium restriction in animal models reduces hepatic DIO1 activity within days. [1] Human data show that patients with combined selenium and iodine deficiency develop myxedematous cretinism at far higher rates than those deficient in iodine alone, a finding from African field studies that first established the clinical relevance of this relationship.

Clinically, a patient with a TSH between 2.5 and 10 mIU/L, ongoing symptoms, and a serum selenium below 70 mcg/L may benefit from selenium repletion before any decision about starting levothyroxine. This does not replace standard thyroid care. A physician should guide that decision using a full panel that includes free T4, free T3, TSH, TPO-Ab, and a serum or whole-blood selenium level.

Selenium and Subclinical Hypothyroidism

Subclinical hypothyroidism (SCH) is defined as a TSH above the upper reference limit (typically 4.5 to 5.0 mIU/L) with free T4 within the normal range. It affects an estimated 3 to 8 percent of the general population and up to 15 to 18 percent of women over 60. [5]

A 2018 randomized trial by Mao et al. enrolled 192 Chinese adults with SCH and randomized them to 100 mcg/day of selenomethionine or placebo for six months. The selenium group showed a statistically significant reduction in TSH (mean decrease 1.1 mIU/L, P<0.05) compared with the placebo group, along with a reduction in TPO-Ab titers. [6] A separate Italian cohort study following 2,143 patients with newly diagnosed SCH for 12 months found that lower serum selenium quartile at baseline independently predicted progression to overt hypothyroidism (hazard ratio 2.3 to 95% CI 1.4 to 3.8). [7]

Not every patient with SCH needs selenium supplementation, and treatment decisions should account for the patient's symptom burden, antibody status, pregnancy status, and cardiovascular risk profile. The 2019 American Thyroid Association guidelines on thyroid dysfunction in pregnancy explicitly state that adequate selenium and iodine intake is relevant to maternal thyroid reserve. [8]

Selenium and Hashimoto's Thyroiditis

Hashimoto's thyroiditis is the most common organ-specific autoimmune disease worldwide, affecting an estimated 5 percent of the global population. It is characterized by lymphocytic infiltration of the thyroid gland, elevated TPO-Ab and Tg-Ab, and progressive destruction of thyroid tissue that usually leads to hypothyroidism over years to decades.

The trial evidence for selenium in Hashimoto's is among the most consistent in nutritional endocrinology. Duntas et al. published a key controlled trial in 2003 (N=65) showing that 200 mcg/day of sodium selenite for 3 months reduced TPO-Ab by 46 percent compared with a 10 percent reduction in the control group (P<0.001). [9] A 2010 follow-up by Mazokopakis et al. (N=80) using 200 mcg/day of selenomethionine for 12 months found a 50 percent reduction in TPO-Ab and improved thyroid echogenicity on ultrasound. [10]

The 2016 Cochrane-style systematic review by Wichman et al. pooled 4 RCTs (N=463) and confirmed that selenium supplementation for 3 to 12 months significantly reduced TPO-Ab (weighted mean difference: 40 percent, P<0.001) and Tg-Ab compared with placebo, with no serious adverse events at 200 mcg/day doses. [2]

Despite this, no major guideline yet recommends universal selenium supplementation for all patients with Hashimoto's thyroiditis. The European Thyroid Association (ETA) position statement from 2015 states: "Selenium supplementation (200 mcg/day) may improve the inflammatory activity in patients with autoimmune thyroid disease," while acknowledging the need for larger trials with quality-of-life endpoints. The ETA cautions against doses above 200 mcg/day given the narrow therapeutic window.

A practical clinical framework for selenium use in Hashimoto's: confirm serum selenium is below 100 mcg/L before starting supplementation, use selenomethionine 200 mcg/day for a minimum 6-month trial, recheck TPO-Ab and serum selenium at 6 months, and discontinue if no antibody reduction occurs or if selenium exceeds 150 mcg/L on recheck. This avoids both under-treatment and the toxicity risk associated with chronic intakes above 400 mcg/day.

Selenium and Graves' Disease

Graves' disease is the leading cause of hyperthyroidism in iodine-sufficient regions. It is an autoimmune condition driven by TSH-receptor antibodies (TRAb) that continuously stimulate the thyroid. Approximately 25 to 50 percent of Graves' patients develop Graves' orbitopathy (GO), an inflammatory eye condition that can cause proptosis, diplopia, and in severe cases vision loss.

The most cited evidence comes from the EUGOGO (European Group on Graves' Orbitopathy) randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2011 (N=159). Patients with mild active Graves' orbitopathy received 200 mcg/day of selenium (as selenomethionine), pentoxifylline, or placebo for 6 months, followed by 6 months of follow-up. At 6 months, 61 percent of the selenium group showed clinical improvement versus 36 percent in the placebo group (P<0.001). Disease progression occurred in only 7 percent of the selenium group versus 26 percent of the placebo group. [11]

The EUGOGO RCT led to the inclusion of selenium in European guidelines for mild Graves' orbitopathy. The 2021 EUGOGO guidelines state: "Selenium 200 mcg/day for 6 months is recommended for patients with mild, active Graves' orbitopathy." [12]

For the thyroid itself in Graves' disease, selenium's benefit is less established. Serum selenium is frequently low in newly diagnosed Graves' patients, and oxidative stress markers are elevated, suggesting selenium depletion is part of the disease process rather than just a bystander. Whether selenium supplementation reduces TRAb or accelerates remission on antithyroid drugs remains under investigation. The ongoing SeGraves trial is addressing this question prospectively.

Dietary Sources of Selenium and How to Hit the Target

The recommended dietary allowance (RDA) for selenium in adults is 55 mcg/day, set by the Institute of Medicine. The tolerable upper intake level (UL) is 400 mcg/day. Chronic intake above 400 mcg/day causes selenosis, which presents as hair loss, brittle nails, garlic breath odor, peripheral neuropathy, and in severe cases, liver damage and cardiac arrhythmia. [3]

Brazil nuts are the most concentrated food source, providing 68 to 91 mcg per nut depending on soil conditions in the growing region. Two Brazil nuts per day can meet or exceed the RDA. Other reliable sources include:

• Yellowfin tuna (92 mcg per 3 oz, cooked)
• Halibut (47 mcg per 3 oz)
• Sardines, canned in oil (45 mcg per 3 oz)
• Beef kidney (140 mcg per 3 oz)
• Eggs (15 mcg each)
• Sunflower seeds (19 mcg per 1 oz)

Dietary selenium bioavailability is generally high for organic forms (selenomethionine from plants and animal proteins) and somewhat lower for inorganic selenite or selenate found in water and some fortified foods. Patients with celiac disease, inflammatory bowel disease, or short bowel syndrome may absorb selenium poorly regardless of dietary intake. These patients warrant serum selenium testing more proactively.

Forms of Selenium Supplements and Dosing Considerations

Not all selenium supplements are clinically equivalent. Selenomethionine is the most bioavailable oral form, reaching approximately 90 percent absorption in healthy adults. Selenium-enriched yeast (a mixture of selenomethionine and other organic selenium compounds) performs similarly. Inorganic sodium selenite reaches roughly 50 to 60 percent absorption and is less preferred for long-term supplementation, though some early Hashimoto's trials used it effectively.

Standard doses used in thyroid trials:

• 200 mcg/day selenomethionine for Hashimoto's thyroiditis (3 to 12 months)
• 200 mcg/day selenomethionine for mild Graves' orbitopathy (6 months per EUGOGO)
• 100 mcg/day in some SCH trials showing TSH benefit

Selenium supplements interact with certain medications. Statin drugs may reduce selenoprotein synthesis independently, compounding any dietary shortfall. Valproic acid and cisplatin can deplete selenium. Patients taking these drugs deserve baseline serum selenium measurement. [13]

Testing serum selenium is the most practical first step. Whole-blood selenium provides a more stable long-term picture since plasma selenium responds quickly to short-term intake changes. Reference ranges for optimal thyroid-related selenoprotein activity cluster between 100 and 150 mcg/L in most laboratory guidelines.

Iodine-Selenium Interaction: A Critical Balance

Selenium and iodine interact in ways that practitioners must account for when optimizing thyroid function. Correcting selenium deficiency without ensuring adequate iodine can, paradoxically, increase thyroid hormone synthesis to a degree that worsens autoimmune thyroid disease in iodine-sufficient individuals. This was observed in population studies from central Africa, where selenium repletion programs in iodine-deficient areas sometimes caused thyroidal necrosis when iodine availability was marginal.

In clinical practice, confirming both iodine and selenium sufficiency before aggressive supplementation of either nutrient is the safer approach. Spot urinary iodine concentration above 100 mcg/L and serum selenium above 70 mcg/L represent reasonable minimum thresholds for most non-pregnant adults. Pregnant and breastfeeding women have higher requirements: the RDA rises to 60 mcg/day and 70 mcg/day respectively for selenium, and iodine requirements increase substantially. [3]

When to Test and Who Should Be Tested

Serum selenium testing is not part of routine thyroid panels in most health systems, but several patient groups should have it measured:

Patients with confirmed autoimmune thyroid disease (Hashimoto's or Graves') who have ongoing symptoms despite optimized levothyroxine or antithyroid drug therapy deserve a serum selenium measurement. So do patients in geographic areas with known low-selenium soils (parts of the UK, Scandinavia, New Zealand, and central and eastern Europe), those with malabsorption syndromes, and patients on total parenteral nutrition.

Women planning pregnancy with known Hashimoto's thyroiditis are a group where selenium status may influence maternal thyroid reserve and the risk of postpartum thyroiditis. One RCT by Negro et al. (N=169) found that 200 mcg/day of selenomethionine given from the first trimester through 12 months postpartum significantly reduced the incidence of postpartum thyroid dysfunction (28.6% vs. 48.6% in the control group, P<0.01) and postpartum depression scores. [14]

A physician-ordered test through a standard clinical laboratory costs roughly $30 to $60. That single data point can meaningfully change management, either by identifying a correctable deficit or by ruling out selenium as a contributing factor when a patient remains symptomatic on thyroid therapy.